From Solanezumab To Solithromycin: What To Watch For In Q4

Lilly’s solanezumab, Roche/Genentech’s Ocrevus and Cempra’s solithromycin are among the key therapies scheduled for major data read-outs or approval decisions in Q4 2016. With the help of Informa Pharma Intelligence’s Biomedtracker, Scrip takes a look at what to expect before we enter the new year.

Of the data read-outs due by the end of 2016, perhaps the most eagerly anticipated is the top-line data from Eli Lilly & Co.’s Phase III EXPEDITION study of solanezumab in mild Alzheimer’s disease – failure here would likely be the last the last straw for the product and potentially the amyloid hypothesis on which it is based.

EXPEDITION-3 was predicated on a subgroup analysis of the failed EXPEDITION-1 and -2 studies. Reported in 2012, they showed that...